Education
About Us
Working with TipRanks
Follow Us
InspireMD Inc (NSPR)
:NSPR
NSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.87 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)48.78K
Market Cap
$79.35M
Enterprise Value$96.28M
Total Cash (Recent Filing)$9.62M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 20, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding30,635,345
10 Day Avg. Volume33,149
30 Day Avg. Volume48,778
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.61
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit63.93
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$5.00Price Target Upside93.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
InspireMD News
PremiumCompany Announcements
InspireMD Inc. Reports 2024 Financial Results and Strategic Progress
PremiumCompany Announcements
InspireMD’s Earnings Call: Cautious Optimism Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInspireMD could be an attractive add-on for major MedTech cardiovascular players like Boston Scientific.
FDA ApprovalFDA approval of CGuard carotid artery stent is seen as InspireMD's most important catalyst.
Market ShareBest-in-class data for CGuard should result in fast share taking in the market.
Bears Say
Competitive LandscapeThe transfemoral carotid artery stenting market has competitors with DSMI rates ranging from 2.3% to 8.3%.
---
Ownership Overview
25.78% Insiders
0.06% Mutual Funds
0.83% Other Institutional Investors
73.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NSPR FAQ
What was InspireMD Inc’s price range in the past 12 months?
InspireMD Inc lowest stock price was $1.87 and its highest was $3.80 in the past 12 months.
What is InspireMD Inc’s market cap?
InspireMD Inc’s market cap is $79.35M.
When is InspireMD Inc’s upcoming earnings report date?
InspireMD Inc’s upcoming earnings report date is May 20, 2025 which is in 24 days.
How were InspireMD Inc’s earnings last quarter?
InspireMD Inc released its earnings results on Mar 12, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.005.
Is InspireMD Inc overvalued?
According to Wall Street analysts InspireMD Inc’s price is currently Undervalued.
Does InspireMD Inc pay dividends?
InspireMD Inc does not currently pay dividends.
What is InspireMD Inc’s EPS estimate?
InspireMD Inc’s EPS estimate is -0.2.
How many shares outstanding does InspireMD Inc have?
InspireMD Inc has 30,635,345 shares outstanding.
What happened to InspireMD Inc’s price movement after its last earnings report?
InspireMD Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 0.717%.
Which hedge fund is a major shareholder of InspireMD Inc?
Currently, no hedge funds are holding shares in NSPR
---
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (93.05% Upside)
$5.00 (93.05% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.24%
12-Months-Change
Fundamentals
Return on Equity
-84.68%
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
---
NSPR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and clinical trial success for CGuard products, alongside anticipated US market expansion. However, increased operating expenses, decreased gross profit margins, and a higher net loss create financial challenges. The sentiment reflects cautious optimism with significant expectations from the US market entry.Read More>---
NSPR Stock 12 Month Forecast
Average Price Target
$5.00
▲(93.05% Upside)
Technical Analysis
Best Analysts Covering NSPR
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+8.73%
assigned a buy rating 7 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.73% per trade.
---